Emergent Biosolutions - Stock Price History | EBS

Historical daily share price chart and data for Emergent Biosolutions since 2021 adjusted for splits. The latest closing stock price for Emergent Biosolutions as of September 23, 2021 is 53.84.
  • The all-time high Emergent Biosolutions stock closing price was 134.94 on August 13, 2020.
  • The Emergent Biosolutions 52-week high stock price is 127.20, which is 136.3% above the current share price.
  • The Emergent Biosolutions 52-week low stock price is 53.06, which is 1.4% below the current share price.
  • The average Emergent Biosolutions stock price for the last 52 weeks is 80.38.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Emergent Biosolutions Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 83.1653 54.0000 134.9400 49.3400 89.6000 66.08%
2019 51.8647 57.7000 66.1600 39.9200 53.9500 -8.99%
2018 56.2235 47.9700 73.2400 44.4400 59.2800 27.57%
2017 34.9138 33.2300 47.7500 28.3000 46.4700 41.50%
2016 33.3817 38.0900 44.2200 24.6000 32.8400 -17.92%
2015 31.9165 26.9000 40.2800 26.2300 40.0100 46.93%
2014 23.8045 24.0200 28.0900 19.9200 27.2300 18.44%
2013 17.2350 16.9000 23.9500 13.0800 22.9900 43.33%
2012 15.0918 17.0000 18.3400 12.9100 16.0400 -4.75%
2011 20.4083 23.7800 24.9800 15.0200 16.8400 -28.22%
2010 17.0443 13.8100 23.8000 13.4600 23.4600 72.63%
2009 15.8787 25.0900 26.2600 9.6200 13.5900 -47.95%
2008 12.3571 5.0900 26.1100 4.9900 26.1100 416.01%
2007 10.3642 11.3000 16.9800 4.7100 5.0600 -54.66%
2006 10.8245 11.7000 11.7000 9.7700 11.1600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.892B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71